Reimagining patient care and future directions in axSpA and PsA – welcome
Speaker: Prof. Xenofon Baraliakos
In this opening video, Prof. Baraliakos (Chair) introduces the faculty, objectives, and agenda for the symposium entitled ‘Reimagining patient care and future directions in axSpA and PsA’.
Understanding axial disease in clinical practice: does it matter?
Speaker: Xenofon Baraliakos (Germany)
In this short summary video, Prof. Baraliakos presents a clinical case study, examining the management of PsA with axial manifestations. He also discusses the first randomized controlled trial with a biologic conducted specifically in patients with PsA and axial manifestations, which demonstrated the efficacy of secukinumab in this patient population.
Speaker: Lianne Gensler (USA)
During this short summary video, Prof. Gensler discusses the importance of assessing patients with PsA for axial disease, highlighting how this diagnosis influences approaches to disease management, including treatment decision making.
In this video, Prof. Baraliakos and Prof. Gensler discuss the management of PsA with axial manifestations and AS in clinical practice. As part of this session, the speakers present two parallel case studies documenting the clinical presentation, diagnostic methods used, and treatment options available for each patient, drawing some comparisons between the two patient journeys.
Putting patients first: safety of IL-17A inhibition
Speaker: Grace Wright (USA)
In this short summary video, Prof. Wright presents key long-term secukinumab safety data from randomized controlled trials and real-world safety data sets, alongside post marketing safety data. This data comprises a broad spectrum of evidence regarding the safety of IL-17A inhibition.
Speaker: Stefan Schreiber (Germany)
During this short summary video, Prof. Schreiber discusses the association of inflammatory bowel disease with psoriasis, PsA, and axSpA. This session also looks at the recent data for IL-17A inhibition and inflammatory bowel disease.
In this discussion chaired by Prof. Baraliakos, Prof. Wright and Prof. Schreiber discuss the safety of IL-17A inhibition in the context of treating patients with PsA or axSpA, focusing on treatment-related safety-risks, the implications of inflammatory bowel disease, and their experiences treating patients with comorbidities, including cardiovascular disease. The discussion also considers the impact of the COVID-19 pandemic on patients with rheumatic disease.
Juvenile psoriatic arthritis and enthesitis-related arthritis: evolving concepts
Chair: Xenofon Baraliakos (Germany), Speaker: Hermine Brunner (USA)
In this video, Prof. Brunner describes the epidemiology, clinical characteristics, and comorbidities associated with enthesitis-related arthritis and juvenile psoriatic arthritis. Prof. Brunner also discusses the unmet needs and challenges associated with the management of these conditions, as well as the latest data regarding biologics that are currently coming to the fore.
Reimagining patient care: committed to innovation
Speaker: Peter Nash (Australia)
In this short summary video, Prof. Nash discusses a recent study that demonstrated the potential for machine learning to identify patient clusters, examining how this can support disease management.
Speaker: Pedro Machado (United Kingdom)
During this short summary video, Prof. Machado discusses the impact of machine learning on the management of axSpA, and to the potential to incorporate machine learning into clinical practice in the future, in order to predict disease outcomes.
In this session chaired by Prof. Baraliakos, Prof. Nash and Prof. Machado discuss advances in artificial intelligence and machine learning that could potentially aid in the diagnosis and management of axSpA and PsA.
Closing remarks
Chair: Xenofon Baraliakos (Germany)
Prof. Baraliakos concludes the symposium by summarizing key learnings from each session.
